Orthopedics at a Crossroads
It's been over a year since VHA launched its orthopedic implant program-and nearly two years since Premier launched its program. To date, neither program has delivered the kinds of business, say insiders, that their manufacturer partners had hoped for. Unless a hospital group owns its hospitals, getting compliance is too difficult.
You may also be interested in...
One of the hottest topics at the 2007 AAOS was the the trend toward resurfacing rather than completely replacing joints damaged by arthritis and other causes. There are a variety of metallic, synthetic and biologic methods used in hip, knee, shoulder and extremity joint resurfacing, many designed for younger patients who wish to remain active and avoid total joint replacement.
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.